Saturday 17 October 2026
Export SPRC’s income statement to Excel — free account
SciSparc Ltd.
SPRC Healthcare Biotechnology
SciSparc Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $856,000.00, down 34.5% from fiscal 2024. Operating cash flow growth for three consecutive years.
1.70
0.30
−15.00%
Follow SPRC
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(119.88%) | 0.00% | 0.00% | 0.00% | |
| (94.45%) | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,532.21%) | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow |
(13.26) | (7.66) | (7.72) | — | |
Capital Expenditures |
— | 0.04 | — | — | |
| Other line items | |||||
Cash ROIC |
(148.94%) | (67.94%) | (197.47%) | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
2.26 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | 0.00 | |
Average Days of Payables |
251.75 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
133.24 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
1.54 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
14.73 | 4.97 | 13.39 | 0.00 | |
Capex/Depreciation |
0.00 | 0.10 | 0.00 | — | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | — | — | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Oct 2026